12th Congress of the European Hematology ... - Haematologica

patients (pts), 36 male, with acute myocardial infarction treated by stent
placement (PCI). After PCI all patients received dual anti-platelet therapy
(ASA-75mg/d and clopidogrel-initial dose 600 mg and next 75 mg/d).
Methods. Following platelet functions were assessed: aggregation induced
by ADP (3.5 and 5.0 umol/L) or collagen (2 ug/mL) as well as the closure
time in PFA-100. The C807T polymorphism of platelet GPIa was investigated
using the PCR method introduced by Santoso et al. Myocardial
destruction was assessed by measurement of troponin I serum level.
Results. In the whole study group the frequency of the T allele was 52,5%,
and in the anti-platelet therapy resistant subgroup (40% of pts) this polymorphism
has been found in 56,3% of pts. There were no differences of
age, infarction location and number of coronary artery lesions between
the groups with CC and CT polymorphism. In pts with the T allele we
observed a higher level of troponin I in the anti-platelet therapy resistant
subgroup in comparison with pts with the C allele. This difference was
not significant in non-resistant pts (Figure 1). Conclusions. This study suggests
a strong association between the presence of platelet GPIa T807
allele and myocardial damage during acute coronary syndrome, especially
in anti-platelet therapy resistant patients.
Figure 1.
1327
UTILITY OF RETICULATED PLATELETS VALUE IN DIFFERENT HEMATOLOGIC DISEASES
A. Lemes, T. Molero, P. Martin, H. Luzardo, J. López, S. De la Iglesia,
A. Suarez
Hospital Universitario de GC Dr Negrín, LAS PALMAS DE GC, Spain
Reticulated platelets are the youngest platelets in the circulation and
contain residual mRNA in their cytoplasm. mRNA can be measured
using flow cytometry. A new automated method to asses reticulated
platelets, the immature platelet fraction (IPF), has been recently incorporated
to the Sysmex XE-2100 hematology autoanalyzer. IPF reflects
thrombopoiesis in bone marrow. Some authors have communicated that
IPF was significantly high in patients with idiopathic thrombocytopenic
purpura (ITP) and recovery phase of post-chemotherapy, while other
investigators think that IPF may be useful to differentiate essential
thrombocytosis from reactive thrombocytosis (RT). The aim of the study
was to obtain the normal values of IPF in our laboratory in healthy
donors and in apheresis product, compared to patients diagnosed with
ITP, myeloproliferative disease (MPD) and RT.
Table 1.
Material and Methods. Peripheral blood (PB) samples in EDTA tubes
from 92 healthy donors, 11 ITP, 13 RT, 6 MPD and 55 platelet apheresis
product were acquired in a Sysmex XE-2100 autoanalyzer employing
XE-Pro Series software. Results. Table 1. Sensibility and specifity of IPF
12 th Congress of the European Hematology Association
were excellent for ITP diagnosis when we apply a cutt-off value of 8.6%
All ITP patients show high IPF at diagnosis and it decreased when
platelet counts rise. Discussions. Results demonstrate the value of IPF
determination in ITP differential diagnosis with high sensibility and
specificity, but not for RT and MPD. More samples must be studied to
confirm these results.
1328
EFFECTS OF COMBINED THERAPY WITH DEFERIPRONE AND DEFEROXAMINE
ON GONADAL FUNCTION IN MALE PATIENTS WITH β-THALASSEMIA MAJOR
K. Farmaki, N. Angelopoulos, C. Pappa, G. Anagnostopoulos,
I. Tzoumari
Korinthos General Hospital, KORINTHOS, Greece
Background. Hypogonadism, mainly of hypogonadotrophic origin represents
one of the major iron-induced complications in patients with βthalassemia
major. β-thalassemia major leads to variable pituitary iron
overload and thus hypophyseal damage. Aims. The purpose of this study
was to investigate the effects of 5 years of intensive chelation with combined
deferoxamine and deferiprone regimen on pituitary- testicular axis
in 9 eugonadal and 7 hypogonadal thalassaemic men, aged from 22 to
44 years (29.8±2.03, mean±SEM) who were previously maintained on
subcutaneous deferoxamine monotherapy. Methods. The protocol of biochemical
investigation included basal serum levels of follicle stimulating
hormone (FSH), luteinizing hormone (LH), and testosterone and
gonadotrophins response after a gonadotrophin-releasing hormone
(GnRH) test. All patients were initially assessed before the beginning of
combined therapy (Between January and October 2001) and reassessed
on July 2006. Substitution therapy was discontinued for 40 days before
the biochemical assessments. Results. According to our results, testosterone
levels were significantly increased in eugonadal patients
(7.67±0.63 vs. 5.71±0.55 ng/mL, p